Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The U.S. equities have experienced a significant performance surge over the past two years.
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.
Indianapolis Star on MSN8d
Eli Lilly will build 4 new manufacturing sites to increase domestic drug productionEli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.
Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer ...
Food and Drug Administration, Eli Lilly and FDA Bars Copies
Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.
LifeMD, Lilly and Teladoc
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
· 18h · on MSN
Teladoc, LifeMD tie up with Lilly's pharmacy partner to offer Zepbound
LifeMD Integrates With LillyDirect to Offer Access of Single-dose Vials of Zepbound
LifeMD on Thursday said it will integrate with Eli Lilly's online pharmacy and healthcare platform to offer access to Lilly's prescription obesity treatment Zepbound in single-dose vials. LifeMD, a virtual primary care services provider,
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out how Lilly could perform through the end of the decade, and decide whether it's still worth investing in the stock.
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more appropriate opportunity for advertising.
Eli Lilly is partnering with Imagine Entertainment and MACRO to drive industry-wide change and guide in authentically representing disease.
Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1,
Some results have been hidden because they may be inaccessible to you
Show inaccessible results